Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the sogroya market?

In the past few years, the market size for Sogroya has witnessed a XX (HCAGR). Projections reveal that it is set to expand from $XX million in 2024 to $XX million in 2025, marking a Compound Annual Growth Rate (CAGR) of XX%. The impressive growth during the historical period can be linked to an increase in medical services for underserved populations, a surge in demand for associated treatments, heightened focus on passenger safety, a rise in diagnostic processes, and improved access to innovative pharmaceuticals.

What will be the sogroya market size in the future?

The forecasted size of the sogroya market is projected to see XX (FCAGR) in the upcoming years. The market is set to escalate to $XX million by 2029, with a compound annual growth rate (CAGR) of XX%.The anticipated growth during the forecast period can be credited to factors such as increasing government initiatives, changes in urban living trends, a rise in the incidence of growth hormone diseases, heightened awareness about healthcare, and expansion within the pharmaceutical industry. Key future predictions involve technological breakthroughs, advancements in biotechnology and recombinant DNA technology, evolution of drug delivery systems, AI-enabled personalized treatments, and a paradigm shift toward preventive medicine.

Get your sogroya market report here!

https://www.thebusinessresearchcompany.com/report/sogroya-global-market-report

What main drivers are fueling expansion in the sogroya market?

The surge in need for hormone replacement therapy (HRT) is expected to bolster the expansion of the sogroya market in the future. HRT is a specialized medical procedure aimed at substituting hormones such as estrogen and progesterone to manage symptoms related to menopause or hormonal imbalances. The demand for Hormone replacement therapy (HRT) is on the rise due to the escalating incidents of hormonal imbalances, increased understanding of its advantages, and improvements in medical interventions that make it more obtainable and effective for handling situations like menopause and growth hormone deficiencies. Sogroya contributes to hormone replacement therapy by offering a once-a-week treatment alternative for individuals suffering from growth hormone deficiency, assisting in the normalization of growth hormone levels, enhancing physical performance, and improving the overall quality of life through an efficient and straightforward dosing plan. For example, in October 2023, the UK’s National Health Service reported that during 2022-23, England had 11 million HRT prescriptions, a 47% growth from 2021-22. Additionally, approximately 2.3 million patients were given HRT prescriptions, indicating a 29% increase relative to the prior year. As a result, the escalating demand for hormone replacement therapy is propelling the growth of the sogroya market.

What key areas define the segmentation of the global sogroya market?

The sogroya market covered in this report is segmented –

1) By Indication: Adult Growth Hormone Deficiency; Pediatric Growth Hormone Deficiency

2) By Formulation: Subcutaneous Injectable; Pre-Filled Syringes

3) By Distribution Channel: Retail Pharmacies; Online Pharmacies

4) By End User: Hospital; Clinicals; Ambulatory Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20358&type=smp

Who are the dominant players expanding their reach in the sogroya market?

Major companies operating in the sogroya market are Novo Nordisk A/S

How are evolving market trends shaping sogroya Strategies?

The predominant trend in the sogroya market is the increased emphasis on obtaining regulatory approval for broadening its indications and improving its accessibility. Regulatory acceptance is the formal consent granted by governmental bodies, ensuring the safety, efficiency, and quality of a drug before it can be sold or recommended. For example, in April 2023, Novo Nordisk A/S, a pharmaceutical firm based in Denmark, achieved the U.S. Food and Drug Administration (FDA) approval for Sogroya, targeted towards treating children 2.5 years and older with growth hormone deficiency. This decision made it the pioneering once-weekly growth hormone treatment for children and adults alike. This novel treatment only requires a subcutaneous injection once a week, thus providing a more readily available option compared to daily injections. This approval relies on the phase 3 REAL4 study, which showed that the height velocity results between Sogroya and traditional daily somatropin were comparable. Typical side effects include nasopharyngitis, headaches, and reactions at the injection site.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20358

Which regions are emerging as leaders in the sogroya market?

North America was the largest region in the sogroya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sogroya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Biosimilar Growth Hormones Global Market Report 2025

https://thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormone Global Market Report 2025

https://thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Global Biosimilar Hormones Global Market Report 2025

https://thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: